Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile -Associated Infection.
| Autor: | Pulse ME; PreClinical Services, UNT System College of Pharmacy, Fort Worth, Texas, USA., Weiss WJ; PreClinical Services, UNT System College of Pharmacy, Fort Worth, Texas, USA., Kers JA; Intrexon Corp., Industrial Products Division, South San Francisco, California, USA., DeFusco AW; Oragenics, Inc., Alachua, Florida, USA., Park JH; Oragenics, Inc., Alachua, Florida, USA., Handfield M; Oragenics, Inc., Alachua, Florida, USA mhandfield@oragenics.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Mar 27; Vol. 63 (4). Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019). |
| DOI: | 10.1128/AAC.01904-18 |
| Abstrakt: | Lantibiotics present an attractive scaffold for the development of novel antibiotics. We report here a novel lantibiotic for the treatment of Clostridium difficile infection. The lead compounds were selected from a library of over 700 single- and multiple-substitution variants of the lantibiotic mutacin 1140 (MU1140). The best performers in vitro and in vivo were further used to challenge Golden Syrian hamsters orally in a Golden Syrian hamster model of Clostridium difficile -associated disease (CDAD) in a dose-response format, resulting in the selection of OG716 as the lead compound. This lantibiotic was characterized by a 50% effective dose of 23.85 mg/kg of body weight/day (10.97 μmol/kg/day) in this model. Upon oral administration of the maximum feasible dose (≥1,918 mg/kg/day), no observable toxicities or side effects were noted, and no effect on intestinal motility was observed. Compartmentalization to the gastrointestinal tract was confirmed. MU1140-derived variants offer a large pipeline for the development of novel antibiotics for the treatment of several indications and are particularly attractive considering their novel mechanism of action. Based on the currently available data, OG716 has an acceptable profile for further development for the treatment of CDAD. (Copyright © 2019 American Society for Microbiology.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|